MUMBAI, India, Aug. 12 -- Intellectual Property India has published a patent application (202611078184 A) filed by Noida Institute Of Engineering And Technology Niet on June 24, 2026, for Angiopep-2 Functionalized Ros-Responsive Exosome-Mimetic Nanovesicles Encapsulating Gsk2606414 For Targeted Glioblastoma Therapy.
Inventors include Abhijit Debnath; and Shruti Varshney.
The application for the patent was published on August 07, 2026, under issue no. 32/2026.
Abstract: The present invention discloses an Angiopep-2 functionalized, reactive oxygen species responsive, exosome-mimetic nanovesicle encapsulating the selective PERK inhibitor GSK2606414 for targeted treatment of glioblastoma multiforme. The nanovesicle comprises a lipid bilayer of hydrogenated soy phosphatidylcholine, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-Angiopep-2 in which a thioketal-linked cleavable lipid bridge, the synthesis of which is fully exemplified, is incorporated, together with a reconstituted monocyte or macrophage plasma membrane protein fraction. Mean hydrodynamic diameter is about 120 nanometres, entrapment efficiency exceeds 80 per cent, and the system releases less than 15 per cent payload in physiological buffer but more than 70 per cent under simulated glioblastoma microenvironment, undergoing receptor-mediated transcytosis across the blood-brain barrier and selectively delivering the PERK inhibitor to glioblastoma cells with markedly enhanced antitumour efficacy and reduced pancreatic an
Disclaimer: Curated by HT Syndication.
